{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:25:57Z","timestamp":1787019957202,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis has a global prevalence of 1\u20133%, with variations observed across different ethnic groups and geographical areas. Disease susceptibility and response to anti-tumor necrosis factor-\u03b1 (TNF\u03b1) drugs suggest different genetic regulatory mechanisms which may include NLR family pyrin domain containing 3 (NLRP3) polymorphism. Evaluation of the NLRP3 gene polymorphism, the serum level of CRP and TNF\u03b1 in psoriasis patients and assessment of the NLRP3 (rs10754558) gene polymorphism, CRP and TNF\u03b1 with disease severity and their role as biomarkers for response to Methotrexate and Adalimumab in psoriasis. The study had a total of 75 patients diagnosed with psoriasis vulgaris, who were compared to a control group of 75 healthy individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was a highly significant difference in NLRP3 genotypes and alleles distribution between psoriasis patients and controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002,0.004). The heterozygote genotype GC (OR\u2009=\u20093.67,95%CI:1.75\u20137.68,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0006), was linked with increased risk of psoriasis. Additionally, The GC genotype was significantly associated with nonresponse to psoriasis therapy (OR\u2009=\u200911.7,95%CI:3.24\u201342.28,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002). Regarding serum CRP and TNF\u03b1 levels, there was a highly statistically significant difference between psoriasis patients and controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and there was also a highly statistically significant difference between responders and non-responders in psoriasis patients regarding PASI 50 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The NLRP3 (rs10754558) genotypes GC was associated with the severe form of psoriasis and with nonresponse to psoriasis medication. Therefore, NLRP3 (rs10754558) gene polymorphism is an important prognostic biomarker in psoriasis patients. The serum TNF\u03b1 can be used as a predictor for response to therapy in psoriasis patients. More research for evaluation of role of the NLRP3 gene polymorphism in the genetic risks and treatment outcomes associated with psoriasis is still required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12865-024-00630-2","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T03:02:16Z","timestamp":1720062136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["NLRP3 (rs10754558) gene polymorphism and tumor necrosis factor alpha as predictors for disease activity and response to methotrexate and adalimumab in psoriasis"],"prefix":"10.1186","volume":"25","author":[{"given":"Fatma Z.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba Allah Mohamed","family":"Hoseiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya A. El","family":"Shahawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Boghdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7013-9209","authenticated-orcid":false,"given":"Alia A. El","family":"Shahawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"3","key":"630_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jid.2020.07.012","volume":"141","author":"D -Verma","year":"2021","unstructured":"Verma D, Fekri SZ, Sigurdardottir G, Bivik Eding C, Sandin C, Enerb\u00e4ck C. Enhanced inflammasome activity in patients with Psoriasis promotes systemic inflammation. J Invest Dermatol. 2021;141(3):586\u2013e5955. https:\/\/doi.org\/10.1016\/j.jid.2020.07.012.","journal-title":"J Invest Dermatol"},{"key":"630_CR2","doi-asserted-by":"publisher","first-page":"201052","DOI":"10.1016\/j.humgen.2022.201052","volume":"33","author":"A -Farag","year":"2022","unstructured":"Farag A, Badr E, Elnaidany N, Gaafar N, Elmadbouh I. Association of NLRP1 (rs878329) and NLRP3 (rs10754558) genes polymorphism in psoriasis vulgaris patients with dyslipidemia. Hum Gene. 2022;33:201052. https:\/\/doi.org\/10.1016\/j.humgen.2022.201052.","journal-title":"Hum Gene"},{"issue":"14","key":"630_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/TACG.S319065","volume":"26","author":"A -ALrefai","year":"2021","unstructured":"ALrefai A, Dawood A, Shehata W, Elhelbawy M, Elhelbawy N. Evaluation of NLRP3 (rs10754558) and PTPN22 (1858\u00a0C\/T) (rs2476601) functional polymorphisms in Psoriasis susceptibility in Egypt. Appl Clin Genet. 2021;26(14):331\u20139. https:\/\/doi.org\/10.2147\/TACG.S319065. PMID: 34345180; PMCID: PMC8324977.","journal-title":"Appl Clin Genet"},{"issue":"6","key":"630_CR4","doi-asserted-by":"publisher","first-page":"e16814","DOI":"10.1016\/j.heliyon.2023.e16814","volume":"9","author":"AA -Awni","year":"2023","unstructured":"Awni AA, Hamed ZO, Abdul-Hassan Abbas A, Abdulamir AS. Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-\u03b1 inhibitors in Iraqi patients with rheumatoid arthritis. Heliyon. 2023;9(6):e16814. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16814. PMID: 37332933; PMCID: PMC10275785.","journal-title":"Heliyon"},{"key":"630_CR5","doi-asserted-by":"publisher","first-page":"847440","DOI":"10.3389\/fnmol.2022.847440","volume":"15","author":"L -Wang","year":"2022","unstructured":"Wang L, Ren W, Wu Q, et al. NLRP3 inflammasome activation: a therapeutic target for cerebral ischemia-reperfusion Injury. Front Mol Neurosci. 2022;15:847440. https:\/\/doi.org\/10.3389\/fnmol.2022.847440. PMID: 35600078; PMCID: PMC9122020.","journal-title":"Front Mol Neurosci"},{"key":"630_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00973-5","author":"FN -Balieva","year":"2023","unstructured":"Balieva FN, Catton L, Clar\u00e9us BW, et al. Treatment preferences in young adults with moderate to severe psoriasis: a qualitative study from the nordic Countries. Dermatol Ther (Heidelb). 2023. https:\/\/doi.org\/10.1007\/s13555-023-00973-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"630_CR7","first-page":"278","volume":"63","author":"WB -Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278\u201385. PMID: 28404701; PMCID: PMC5389757.","journal-title":"Can Fam Physician"},{"key":"630_CR8","unstructured":"Uaratanawong R, Uaratanawong S, Chunhasewee C, Chawvavanich P. High Sensitivity C-Reactive Protein Level and Psoriasis Severity in Thai Patients. J Med Assoc Thai. 2016;99(9):1039-45. PMID: 29927210."},{"key":"630_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.abd.2020.02.008","volume":"95","author":"MC -Sirin","year":"2020","unstructured":"Sirin MC, Korkmaz S, Erturan I, et al. Evaluation of monocyte to HDL cholesterol ratio and other inflammatory markers in patients with psoriasis. Bras Dermatol. 2020;95:575\u201382.","journal-title":"Bras Dermatol"},{"key":"630_CR10","first-page":"606","volume":"12","author":"MJ -Yazdanpanah","year":"2021","unstructured":"Yazdanpanah MJ, Vahabi-Amlashi S, Nematy M, Shaelaei N, Mohajeri SAR, Tafazzoli Z. Association of serum lipid profiles and dietary intakes of vitamin E and fiber with psoriasis severity. Casp J Intern Med. 2021;12:606\u201312.","journal-title":"Casp J Intern Med"},{"key":"630_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","volume":"50","author":"CS -Carlin","year":"2004","unstructured":"Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859\u201366.","journal-title":"J Am Acad Dermatol"},{"key":"630_CR12","doi-asserted-by":"publisher","unstructured":"Rajguru JP, Maya D, Kumar D, Suri P, Bhardwaj S, Patel ND. Update on psoriasis: a review. J Fam Med Prim Care. 2020;9(1):20\u20134. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_689_19. PMID: 32110559; PMCID: PMC7014874.","DOI":"10.4103\/jfmpc.jfmpc_689_19"},{"key":"630_CR13","doi-asserted-by":"publisher","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.\u00a0https:\/\/doi.org\/10.3390\/ijms20061475. PMID: 30909615; PMCID: PMC6471628.","DOI":"10.3390\/ijms20061475"},{"key":"630_CR14","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"28","author":"R -Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. Global psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;28:369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590. PMID: 32467098; PMCID: PMC7254147.","journal-title":"BMJ"},{"issue":"2","key":"630_CR15","doi-asserted-by":"publisher","first-page":"e010","DOI":"10.1097\/JW9.0000000000000010","volume":"13","author":"C -Guillet","year":"2022","unstructured":"Guillet C, Seeli C, Nina M, Maul LV, Maul JT. The impact of gender and sex in psoriasis: what to be aware of when treating women with psoriasis. Int J Womens Dermatol. 2022;13(2):e010. https:\/\/doi.org\/10.1097\/JW9.0000000000000010. PMID: 35619672; PMCID: PMC9112394.","journal-title":"Int J Womens Dermatol"},{"issue":"4","key":"630_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jaci.2009.07.044","volume":"124","author":"Y -Hitomi","year":"2009","unstructured":"Hitomi Y, Ebisawa M, Tomikawa M, et al. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphy laxis and aspirin-induced asthma. J Allerg Clin Immunol. 2009;124(4):779\u201385.","journal-title":"J Allerg Clin Immunol"},{"key":"630_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ofid\/ofy075","volume":"5","author":"S -Ravimohan","year":"2018","unstructured":"Ravimohan S, Nfanyana K, Tamuhla N, Tiemessen CT, Weissma D, Bisson GP. Common variation in NLRP3Is associated with early death and elevated inflammasome biomarkers among advanced HIV\/TB co-infected patients in Botswana. Open Forum Infect Dis. 2018;5:75.","journal-title":"Open Forum Infect Dis"},{"key":"630_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1042\/CS20160645","volume":"131","author":"N -Irrera","year":"2017","unstructured":"Irrera N, Vaccaro M, Bitto A, et al. BAY 11-7082 inhibits the NF-\u03baB and NLRP3 infl ammasome pathways and protects against IMQ-induced psoriasis. Clin Sci (Lond). 2017;131:487\u201398.","journal-title":"Clin Sci (Lond)"},{"key":"630_CR19","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s13555-023-01014-x","volume":"13","author":"G -Girolomoni","year":"2023","unstructured":"Girolomoni G, Savage L, Gisondi P, et al. Increasing Access to Effective systemic treatments in patients with moderate-to-severe psoriasis. Narrative Rev Dermatol Ther (Heidelb). 2023;13:2171\u201385.","journal-title":"Narrative Rev Dermatol Ther (Heidelb)"},{"issue":"1","key":"630_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Y -Jiang","year":"2023","unstructured":"Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35\u201355.","journal-title":"BioDrugs"},{"key":"630_CR21","doi-asserted-by":"publisher","unstructured":"Farshchian M, Ansar A, Sobhan M, Hoseinpoor V. C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B. Bras Dermatol 2016 Sep-Oct;91(5):580\u20133. https:\/\/doi.org\/10.1590\/abd1806-4841.20164655. PMID: 27828628; PMCID: PMC5087213.","DOI":"10.1590\/abd1806-4841.20164655"},{"issue":"12","key":"630_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/jdv.12372","volume":"28","author":"BE -Strober","year":"2014","unstructured":"Strober BE, Poulin Y, Teller C, Wang Y, Williams DA, Goldblum OM. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. J Eur Acad Dermatol Venereol. 2014;28(12):1701\u20136. https:\/\/doi.org\/10.1111\/jdv.12372. Epub 2014 Jan 15. PMID: 24422992.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"630_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5336\/dermato.2020-74503","volume":"30","author":"D -Demir","year":"2020","unstructured":"Demir D, Akta\u015f E, K\u0131vanc AI, Ozturk F. Impact of treatment with methotrexate and TNF alpha inhibitors on insulin resistance in patients with psoriasis. Turkiye Klinikleri Dermatoloji. 2020;30:35\u201343. https:\/\/doi.org\/10.5336\/dermato.2020-74503.","journal-title":"Turkiye Klinikleri Dermatoloji"},{"issue":"4","key":"630_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12291-011-0156-9","volume":"26","author":"B -Verghese","year":"2011","unstructured":"Verghese B, Bhatnagar S, Tanwar R, Bhattacharjee J. Serum cytokine profile in psoriasis-a case-control study in a tertiary care hospital from northern India. Indian J Clin Biochem. 2011;26(4):373\u20137.","journal-title":"Indian J Clin Biochem"},{"key":"630_CR25","doi-asserted-by":"crossref","unstructured":"Kyriakou A, Patsatsi A, Vyzantiadis TA, Sotiriadis D. Serum levels of TNF-\u03b1,IL-12\/23 p40,andIL-17 in Psoriatic Patients with and without nail psoriasis: a cross-sectional study. Sci World J. 2014;1\u20134.","DOI":"10.1155\/2014\/508178"},{"issue":"1","key":"630_CR26","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1038\/s41598-019-43899-9","volume":"9","author":"SC -Furiati","year":"2019","unstructured":"Furiati SC, Catarino JS, Silva MV, et al. Th1, Th17, and Treg responses are differently modulated by TNF-\u03b1 inhibitors and methotrexate in Psoriasis patients. Sci Rep. 2019;9(1):7526. https:\/\/doi.org\/10.1038\/s41598-019-43899-9. PMID: 31101850; PMCID: PMC6525159.","journal-title":"Sci Rep"},{"issue":"2021","key":"630_CR27","first-page":"101050","volume":"27","author":"MM Hagag","year":"2021","unstructured":"Hagag MM, Ghazy MM, Elhelbawy NG. Tumor necrosis factor \u03b1 gene promoter 308 and 238 polymorphisms and its serum level in psoriasis. Biochem Biophys Rep. 2021;27(2021):101050.","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"630_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5455\/msm.2022.33.40-43","volume":"34","author":"N -Ovcina-Kurtovic","year":"2022","unstructured":"Ovcina-Kurtovic N, Kasumagic-Halilovic E. Serum levels of Tumor Necrosis factor - alpha in patients with psoriasis. Mater Sociomed. 2022;34(1):40\u20133. https:\/\/doi.org\/10.5455\/msm.2022.33.40-43. PMID: 35801072; PMCID: PMC9229364.","journal-title":"Mater Sociomed"},{"issue":"5","key":"630_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1346-8138.2010.01018.x","volume":"38","author":"MF -Abdel-Hamid","year":"2011","unstructured":"Abdel-Hamid MF, Aly DG, Saad NE, Emam HM, Ayoub DF. Serum levels of interleukin-8, tumor necrosis factor-\u03b1 and \u03b3-interferon in Egyptian psoriatic patients and correlation with disease severity. Dermatol. 2011;38(5):442\u20136.","journal-title":"Dermatol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-024-00630-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-024-00630-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-024-00630-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T03:05:07Z","timestamp":1720062307000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-024-00630-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1186\/s12865-024-00630-2","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Zagazig University (IRB# 11123- 17\/10\/2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}